Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Phase I Study of Carfilzomib in combination with Cyclophosphamide and Etoposide for Children with Relapsed or Refractory Solid Tumors and Leukemias
A study of the safety of carfilzomib for children with solid tumors and leukemias that returned or did not respond to previous treatment.
Diagnosis of relapsed or refractory solid tumor. Age 6 months to less than 30 years at enrollment. Must be fully recovered from effects of previous treatment. Life expectancy greater than or equal to 3 months.
Exclusion Criteria:
Prior treatment with carfilzomib. Known allergy to Captisol®. Down syndrome.